Both compounds are REV-ERB receptor agonists from the same laboratory of Thomas Burris (Scripps Research Institute), described in parallel in the publication by Solt et al. 2012. They differ in chemical structure and minor pharmacokinetic properties, but the primary molecular target – REV-ERBα/β receptors – remains common. SR-9009 has gained greater recognition under the trade name “Stenabolic”, and SR-9011 functions as its structural analogue. In laboratory tests, they are sometimes used interchangeably as REV-ERB pharmacology tools; SR-9011 often serves as a reference compound in structure-activity analyses.
SR9011 60 caps
SR-9011 10 mg × 60 capsules is a small organic molecule from the laboratory of Thomas Burris (Scripps Research Institute), an agonist of REV-ERBα/β nuclear receptors (NR1D1/NR1D2) and a structural analogue of SR-9009 (Stenabolic). Described in Nature 2012 as a modulator of the molecular circadian clock and metabolism – BMAL1 repression, mitochondrial biogenesis, “exercise mimetic” in a mouse model.
SR-9011 10 mg 60 capsules - REV-ERB receptor agonist
- SR-9011: a REV-ERB receptor agonist and SR-9009 analogue.
- 10 mg per capsule; pack of 60 capsules.
- Research Use Only reagent, not a medicinal product.
Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.
SR-9011 is a small organic molecule in the class of REV-ERB nuclear receptor agonist — agonist of both REV-ERBα (NR1D1) and REV-ERBβ (NR1D2) isoforms. The substance was created in a laboratory Thomas Burris at Scripps Research Institute — the same team that developed the ERR pan-agonist a decade later SLU-PP-332 100mcg. SR-9011 and its sister compound SR-9009 (Stenabolic) were described in a groundbreaking publication Solt et al. 2012 (Nature) as the first synthetic REV-ERB agonists capable of retuning the circadian rhythm and metabolic program in mouse models.
In a chemical context, SR-9011 belongs to a class small organic molecules in the pharmacology of nuclear receptors – this is an important distinction between peptides (BPC-157, TB-500, MOTS-c) and non-steroidal SARMs (RAD-140). The central axis of the mechanism is the feedback of the molecular circadian clock with mitochondrial metabolism: REV-ERB receptors constitute one of the core components of the cellular clock, and at the same time regulate the expression of β-oxidation and mitochondrial biogenesis genes in skeletal muscles.
For this reason, REV-ERB agonists are classified among so-called “exercise mimetics” — molecules that partially replicate the biochemical phenotype of endurance exercise. This reagent is supplied in a 60 capsules of 10 mg SR-9011 — form adapted to laboratory research protocols operating at working concentrations in vivo on animal models and in vitro on cell lines. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.
Regulatory status (critical)
SR-9011 has not completed any phase of human clinical trials. Compound remains at the stage of preclinical research (rodent models, cell cultures). No registration as a drug with the EMA, FDA or anywhere in the world. Not authorized by EFSA as an ingredient of a dietary supplement. Communicating a product as an “exercise in a pill”, “fat burner” or “endurance booster for athletes” is inconsistent with the Research Use Only framework.
REV-ERB receptors and the circadian clock
REV-ERBα (encoded by the NR1D1 gene) and REV-ERBβ (NR1D2) are nuclear receptors belonging to the nuclear hormone receptor superfamily. They are distinguished by a rare feature in this family – the physiological ligand of REV-ERB is heme (heme), an iron-containing prosthetic group. Binding of heme in the ligand domain switches the receptor into an active repressor conformation.
REV-ERB receptors work in the opposite way to classic transcription activators: after activation they repress expression of target genes by recruiting the corepressor NCoR and the histone deacetylase HDAC3. The most important transcriptional target of REV-ERB is the gene BMAL1 (ARNTL) — one of the two core activators of the molecular circadian clock. The cellular clock acts as a feedback loop: the CLOCK–BMAL1 complex triggers the transcription of the Period (PER) and Cryptochrome (CRY) genes, and in parallel activates the expression of REV-ERB, which then represses BMAL1, completing the rhythmic oscillation with a period close to 24 hours.
REV-ERB is therefore an integral, rhythmically oscillating component of the molecular clock, connecting biological time with metabolism. The biological functions of REV-ERB include gene expression programs of fundamental importance for chronobiology and energy metabolism:
- Regulation of circadian rhythm — BMAL1 repression as one of the arms of the main loop of the molecular clock; stabilization of the period and amplitude of daily oscillations
- Lipid metabolism — repression of lipogenesis genes in the liver, modulation of fatty acid synthesis and lipid profile
- Mitochondrial biogenesis in skeletal muscles — REV-ERBα regulates the number and oxidative capacity of mitochondria in muscle tissue
- Glucose metabolism — participation in the rhythmic regulation of hepatic gluconeogenesis and energy homeostasis
- Modulation of the inflammatory response — repression of pro-inflammatory genes in macrophages (REV-ERB–NF-κB axis)
- Regulation of sleep and locomotor activity — coupling the molecular clock with the circadian activity pattern (rodent models)
For this reason, pharmacological activation of REV-ERB receptors has been treated for over a decade as an interesting target in the search for molecules that modulate both the circadian rhythm and the metabolic program – at the interface of chronobiology and exercise metabolism.
What is SR-9011?
Chemically, SR-9011 is a synthetic small organic molecule designed with affinity for the ligand pocket of REV-ERB receptors, mimicking the agonist effect of heme.
- Common name: SR-9011 (analogue of SR-9009 / Stenabolic)
- Laboratory of Origin: Thomas Burris, Scripps Research Institute
- Pharmacological class: REV-ERBα (NR1D1) + REV-ERBβ (NR1D2) receptor agonist
- Molecular function: circadian rhythm and metabolism modulator; exercise mimetic
- Molecular type: small organic molecule (NOT peptide, NOT steroid)
- Delivered form: HPMC hard capsule, 10 mg of active substance per capsule, 60 capsules; pharmaceutical grade ≥98% HPLC
Table of physicochemical characteristics
| Parameter | Value |
|---|---|
| Name | SR-9011 |
| Pharmacological class | REV-ERBα/β (NR1D1/NR1D2) agonist |
| CAS number | 1379686-29-9 (to be verified at COA) |
| Molecular weight | ~478 g/mol (for verification) |
| Molecular type | A small organic molecule |
| Purity | ≥98% (HPLC) |
| Form | HPMC capsule, 10 mg/capsule, 60 capsules |
| Identity confirmation | Mass spectrometry (MS Q-TOF) |
| Storage conditions | Room temperature (15-25°C), away from light and moisture |
| Shelf life | 24 months (lot details – COA) |
Origin: SR-9011 was created as part of a systematic program to search for synthetic REV-ERB receptor ligands conducted in the laboratory of Thomas Burris – one of the leading specialists in the pharmacology of nuclear receptors (REV-ERB, ERR, PPAR). SR-9009 and SR-9011 are sister REV-ERB agonists described in parallel: in the team’s classic publication (Solt et al. 2012, Nature), both compounds changed the circadian pattern of clock gene expression, modulated lipid and glucose metabolism, and influenced locomotor activity in mice.
Later work (Woldt et al. 2013, Nature Medicine) focused on the REV-ERBα–muscle performance axis, reporting increases in mitochondrial biogenesis and running endurance in rodents.
SCIENTIFIC PERSPECTIVE
All pharmacological data on SR-9011 are from preclinical models (mouse, muscle cell lines, hepatocytes, macrophages). All observations regarding endurance, mitochondrial biogenesis, lipid profile and circadian rhythm require confirmation in human clinical trials – no such studies have been performed to date. Importantly, the oral bioavailability of SR-9011 is poor: in experimental work, the compound was administered to mice via the intraperitoneal (i.p.) route, not orally. Extrapolation of PK/PD profiles to humans requires special caution.
Mechanism of action at the molecular level
SR-9011 binds to the ligand-binding domain of REV-ERBα and REV-ERBβ receptors, mimicking the agonist effect of the natural heme ligand. Binding of the molecule stabilizes the repressor conformation of the receptor, increasing the recruitment of the corepressor NCoR and the deacetylase HDAC3, which leads to enhanced repression of REV-ERB target genes. Pharmacological profile observed in preclinical models – six axes of action:
- REV-ERB agonism and molecular clock repression — as a heme-binding nuclear receptor, REV-ERB, when activated by SR-9011, increases the repression of transcription of target genes, including BMAL1 and other core genes of the circadian clock. This is a direct interference in the feedback loop of the molecular oscillator
- Mitochondrial biogenesis and β-oxidation in skeletal muscle — activation of REV-ERBα in muscle increases the number and oxidative capacity of mitochondria and intensifies the oxidation of fatty acids; improvement in running endurance was reported in mouse models, which is the basis for the term “exercise mimetic”
- Regulation of lipid and glucose metabolism — repression of hepatic lipogenesis genes, reduction of fatty acid synthesis and influence on the lipid profile; participation in the rhythmic control of glucose metabolism
- Circadian rhythm modulation — REV-ERB as an integral component of the molecular clock; pharmacological retuning of the amplitude and phase of circadian oscillations observed in animal models
- Reduction of fat mass in a diet-induced obesity (DIO) model — in mice on a high-fat diet, a decrease in adipose tissue mass was reported without caloric restriction, in connection with increased energy expenditure
- Effect on sleep and locomotor activity — modulation of the circadian pattern of activity and sleep parameters in rodent models, resulting from the coupling of REV-ERB with the molecular clock
Pharmacokinetic profile (based on preclinical models):
- Oral bioavailability: weak — in the studies, the compound was administered intraperitoneally (i.p.), not orally; oral exposure in humans remains uncharacterized
- Human PK profile: uncharacterized – no phase I studies
- Molecular target: ligand-binding domain of REV-ERBα/β receptors, enhancement of transcriptional repression by the NCoR/HDAC3 axis
The REV-ERB mechanism activates one axis from many components of the body’s response to physical exercise and the circadian rhythm. Endurance training simultaneously affects the cardiovascular system, skeletal system, central nervous system, hormonal balance and inflammatory profile. Pharmacological activation of REV-ERB receptors replicates part of the skeletal muscle metabolic program and retunes the molecular clock – but nothing else.
SR-9011 vs SR-9009 and position in the “exercise mimetics” class
There are two common misconceptions surrounding SR-9011: confusion with its sister SR-9009 (Stenabolic) and the identification of all “exercise mimetics” as one category. Both require distinction.
SR-9011 and SR-9009 (Stenabolic). Both compounds are REV-ERB agonists from the same Burris laboratory, described in the same publication by Solt et al. 2012. They differ in chemical structure and minor pharmacokinetic properties, but the primary molecular target – REV-ERBα/β receptors – is common. SR-9009 gained greater market recognition under the trade name “Stenabolic”; SR-9011 functions as its structural analogue. From a laboratory standpoint, both are sometimes used interchangeably as tools to study the pharmacology of REV-ERB, and SR-9011 often serves as a reference compound in SAR (structure-activity) analyses. The sister compound is available as Stenabolic SR-9009.
Three different families of “exercise mimetics”. The term “exercise mimetic” covers molecules with completely different molecular targets – they share only partial replication of the biochemical exercise phenotype, not a common mechanism.
| Class | Example | Molecular target | Mechanism | Status |
|---|---|---|---|---|
| REV-ERB agonist | SR-9011, SR-9009 | REV-ERBα/β (NR1D1/NR1D2) | Repression of the molecular clock (BMAL1), mitochondrial biogenesis, lipid metabolism | RUO research chemicals (Nature 2012) |
| ERR pan-agonist | SLU-PP-332 | ERRα/β/γ | Induction of mitochondrial biogenesis through the ERR–PGC-1α axis | RUO research chemicals (Nature Metabolism 2024) |
| PPARδ agonist | GW-501516 (Cardarine), GW-0742 | PPARδ | β-oxidation of fatty acids | RUO research chemical (carcinogenesis signal in long-term studies in rodents) |
The SR-9011 has the distinction of being the only one of the three classes in operation by the molecular circadian clock — its target (REV-ERB) is a core component of the circadian oscillator, not solely a metabolic regulator. The related pan-agonist SLU-PP-332 targets the ERR–PGC-1α network (mitochondrial biogenesis without direct interference with the clock), and the agonist GW-0742 modifies lipid oxidation by a neighboring node of the metabolic network.
For a comparison of this class, it is worth reading the review Cardarine for weight loss, discussing the PPARδ agonist from a metabolism and reduction perspective. Three distinct receptors, three mechanisms, one common phenotypic denominator – making them the subject of comparative analyzes in exercise metabolism research and within categories SARMs for fat burning.
Applications in scientific research
SR-9011 is used in research work in several areas. In vivo models (mouse) examine its impact on the rhythmic expression of molecular clock genes (BMAL1, PER, CRY), markers of mitochondrial biogenesis, running endurance parameters (treadmill tests), lipid profile and the daily pattern of locomotor activity and sleep. In vitro models (muscle cell lines, hepatocytes, macrophages) measure the kinetics of transcriptional repression, analyze cellular respiration (OCR/ECAR on Seahorse platforms) and study the REV-ERB-inflammation axis. Specific research directions include:
- Molecular chronobiology — pharmacological retuning of the circadian clock, mapping of BMAL1 repression, research on the synchronization of peripheral oscillators with the central clock in the suprachiasmatic nucleus
- Mouse models of mitochondrial endurance and metabolism — treadmill tests, indirect calorimetry, energy expenditure measurements, muscle oxidative capacity analysis
- Experiments on “exercise mimetics” — comparative pharmacological studies in the paradigm of mitochondrial endurance and adaptation, with SR-9011/SR-9009 as REV-ERB agonists alongside ERR and PPARδ agonists
- Studies of lipid metabolism and obesity — DIO (diet-induced obesity) models, analysis of hepatic lipogenesis, lipid profile and body composition
- Pharmacology of nuclear receptors — characterization of REV-ERB ligands, SAR analyses, studies of selectivity towards REV-ERBα/β and interaction with the NCoR/HDAC3 corepressor
- Inflammation research — modulation of the REV-ERB–NF-κB axis in macrophages, rhythmic control of pro-inflammatory gene expression
Summary
SR-9011 (10 mg × 60 capsules) is a small organic molecule of the REV-ERB agonist class (REV-ERBα/β, NR1D1/NR1D2) from the laboratory of Thomas Burris (Scripps Research Institute), described along with its sister SR-9009 in the seminal publication by Solt et al. 2012 (Nature). In mouse models, the compound retunes the molecular circadian clock by repressing BMAL1, enhances mitochondrial biogenesis and β-oxidation in skeletal muscles (REV-ERBα axis – performance, Woldt et al. 2013), reduces fat mass in the DIO model, and modulates the lipid profile and locomotor activity.
SR-9011 combines chronobiology with exercise metabolism – it is the only one of the three main classes of “exercise mimetics” that act through the molecular circadian clock, unlike ERR pan-agonists (SLU-PP-332) and PPARδ agonists (GW-0742, Cardarine). Oral bioavailability is poor (i.p. administration in studies). HPLC purity ≥98%, MS Q-TOF confirmation, COA for each batch. Regulatory Status – Research Use Only; no clinical phase in humans; WADA: class S4.4.1 (metabolic modulators, named), prohibited at all times.
Bibliography
- Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, et al. (2012). Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists. PubMed
- Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoute J, et al. (2013). Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. PubMed
- Sulli G, Manoogian ENC, Taub PR, Panda S (2018). Training the circadian clock, clocking the drugs, and drugging the clock to prevent, manage, and treat chronic diseases. PubMed
- Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, et al. (2013). Nuclear receptors and their selective pharmacological modulators. PubMed
- Amador A, Wang Y, Banerjee S, Kamenecka TM, Solt LA, Burris TP (2016). Pharmacological and genetic modulation of REV-ERB activity and expression affects orexigenic gene expression. PubMed
FAQ
REV-ERBα (NR1D1) and REV-ERBβ (NR1D2) are nuclear receptors whose natural ligand is heme. Once activated, they act as transcriptional repressors – they silence the expression of target genes by recruiting the corepressor NCoR and the deacetylase HDAC3. The most important target is the BMAL1 gene, a core activator of the molecular circadian clock. REV-ERB is therefore an integral, rhythmically oscillating component of the cellular clock, linking biological time with lipid and glucose metabolism and mitochondrial efficiency. SR-9011 mimics the agonistic effect of heme, enhancing this transcriptional repression.
The term refers to the partial replication of the biochemical phenotype of endurance training in an animal model without the training itself. In studies (Woldt et al. 2013), mice treated with the REV-ERB agonist showed an increase in mitochondrial biogenesis and longer running time on the treadmill. “Exercise in a pill” is a journalistic simplification – in experimental pharmacology, “exercise mimetic” means a transcriptional and metabolic pattern analogous to training adaptation, described in an animal model, not a substitute for exercise. SR-9011 additionally retunes the circadian clock, which the ERR and PPARδ agonists do not.
In preclinical studies, SR-9011 and SR-9009 were administered to mice via the intraperitoneal route (i.p. injection) rather than orally – due to poor bioavailability after oral administration. Molecules of this class are characterized by limited metabolic stability and an unfavorable pharmacokinetic profile when administered through the gastrointestinal tract. Oral exposure in humans remains completely uncharacterized – this is one of the main reasons why the compound has not reached the clinical stage and remains a research tool. In laboratory conditions, the choice of route of administration depends on the experimental design.
Yes. The 2026 WADA Prohibited List names SR-9009 and SR-9011 among Rev-Erb-α agonists in class S4.4.1 — metabolic modulators, the same class that covers GW-501516 (Cardarine). Both compounds are prohibited at all times, in and out of competition. Registered Athletes (ADAMS) must verify the current list before making any decision.
NO. Publicly available clinical data (Phase I/II/III) in humans do not exist. The entire evidence base is based on mouse models and cell cultures. SR-9011 remains a preclinical compound – poor oral bioavailability and an uncharacterized pharmacokinetic profile in humans are significant translational barriers. The long-term safety profile has not been described in any human population, and because REV-ERB regulates cardiac circadian rhythm, the theoretical cardiovascular implications of long-term activation of this axis remain unknown. The broader metabolic context of this class is discussed in the article SR-9011 fat burner.
-
Eryk
Polski
Product review
Bardzo szybka dostawa!